Global Diabetic Growth by 2020
Nephropathy
Market
Highest
With 366 million people expected to be affected by diabetes in 2030, the diabetic nephropathy market is expected to grow consistently. The market was worth US$2,262.2 million in 2014 and, at a 5.6% CAGR during the period between 2014 and 2020, it is expected to reach US$3,145.9 million by 2020. Rising Number of Diabetic Patients Worldwide to Fuel Diabetic Nephropathy Market Diabetic nephropathy is a serious condition associated with the kidneys, where increased levels of protein, especially albumin, are present in urine. In a patient affected with diabetic nephropathy, albumin in the urine increases to potentially fatal amounts. The increasing prevalence of diabetes has primarily fueled the diabetic nephropathy market. According to the World Health Organization (WHO), about 9% adults aged above 18 years were affected by diabetes worldwide in 2014. By 2030, the disease is expected to be the seventh leading cause of death worldwide. As diabetes is commonly associated with obesity, the diabetic nephropathy market is estimated to grow along with the rising number of obese people across the globe. The increasing investment in research and development of drugs to treat diabetic nephropathy will boost the overall market. Nowadays, there is increased awareness among people about diabetes and kidney-related disorders. This will further help the market grow, particularly in previously unexplored regions. However, the long duration of clinical trials, in conjunction with the strict regulatory requirements by authorities such as the European Medicines Agency and the U.S. Food and Drug Administration will slow down the growth of the diabetic nephropathy market. Lack of comprehensive therapeutic management will also affect the growth of the overall market. The increasing usage of combination therapy to treat the condition is gaining popularity and is expected to be the key market trend during the forecast horizon. Browse the full report : http://www.mrrse.com/diabetic-nephropathy-market Angiotensin-converting Enzyme (ACE) Inhibitors to be Key Disease Modifying Therapy The diabetic nephropathy market has been segmented on the basis of the disease modifying therapy into angiotensin receptor blockers, angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, renin inhibitors, diuretics, antioxidant inflammation modulator, monocyte chemoattractant proteins inhibitor, connective tissue growth factor inhibitors, G-protein coupled receptors, and endothelin-A receptor antagonist. As hypertension is usually a consequence of diabetic nephropathy, use of antihypertensive agents is usually prescribed in the treatment. ACE inhibitors can reduce the level of progression of the disease by a greater degree than other hypertensive agents and hence this segment is expected to grow significantly. North America Leads Global Diabetic Nephropathy Market
Globally, the diabetic nephropathy market has been divided into Asia, North America, and Europe. North America has been leading the overall market, followed by Europe. According to the American Diabetes Association, in the U.S. alone, around 40% of new cases of diabetic nephropathy have been reported in the recent past. The U.S. and Canada will contribute significantly to the diabetic nephropathy market in North America. Asia is expected to be the fastest growing region of the market during the forecast period, with rising number of patients in Japan, China, and India affected with the condition. Key Players of the Diabetic Nephropathy Market Some of the key players of the diabetic nephropathy market include Pfizer Inc., Novartis AG, Sanofi, and Bayer AG, among others. Table of Content Chapter 1 Preface 1.1 Report Description 1.2 Research Methodology 1.3 Assumptions Chapter 2 Market Synopsis Chapter 3 Porter’s Five Forces Analysis 3.1 Bargaining Power of Suppliers 3.2 Bargaining Power of Buyers 3.3 Threat of New Entrants 3.4 Threat of Substitutes 3.5 Intensity of Rivalry Chapter 4 Industry Overview 4.1 Market Definition 4.2 Market Drivers 4.2.1 Increasing prevalence of diabetes 4.2.2 Globally rising obesity increasing the prevalence of diabetes 4.2.3 Increasing R&D investments in drug discovery and development 4.2.4 Rising awareness among people about diabetes and kidney-related disorders 4.3 Impact Analysis of Market Drivers 4.4 Market Restraints 4.4.1 Strict regulatory requirements and long approval time for drugs 4.4.2 Lack of comprehensive therapeutic management for diabetic nephropathy 4.5 Impact Analysis of Market Restraints 4.6 Market Trends 4.6.1 Increasing usage of combination therapy is gaining popularity in diabetic nephropathy market Send An Enquiry : http://www.mrrse.com/enquiry/119
Chapter 5 Global Market Size and Forecast Chapter 6 Market Size and Forecast by Mode of Treatment 6.1 Disease Modifying Therapies 6.1.1 Angiotensin-Converting Enzyme Inhibitors 6.1.2 Angiotensin Receptor Blockers 6.1.3 Diuretics 6.1.4 Calcium Channel Blockers 6.1.5 Renin Inhibitors 6.1.6 Connective Tissue Growth Factor Inhibitors 6.1.7 Antioxidant Inflammation Modulator 6.1.8 Monocyte Chemoattractant Proteins Inhibitor 6.1.9 Endothelin-A Receptor Antagonist 6.1.10 G Protein-Coupled Receptors Chapter 7 Market Size and Forecast by Geography 7.1 North America 7.1.1 Scenario in the U.S. 7.1.2 Scenario in Canada 7.2 Europe 7.2.1 Scenario in Germany 7.2.2 Scenario in France 7.2.3 Scenario in the U.K. 7.3 Asia 7.3.1 Scenario in Japan 7.3.2 Scenario in China 7.3.3 Scenario in India Chapter 8 Pipeline Drugs for Diabetic Nephropathy 8.1 Drugs Under Development for Diabetic Nephropathy Chapter 9 Competitive Scenario 9.1 Competitive Benchmarking Chapter 10 Company Profiles 10.1 Novartis AG 10.1.1 Company overview 10.1.2 Products and services 10.1.3 Financial performance 10.1.4 Key developments 10.2 Merck & Co., Inc. 10.2.1 Company overview 10.2.2 Products and services
10.2.3 Financial performance 10.2.4 Key developments 10.3 Pfizer, Inc. 10.3.1 Company overview 10.3.2 Products and services 10.3.3 Financial performance 10.3.4 Key developments
UpComing Report :•
Turpentine Market - Global Industry Expert Opinions Analysis, Emerging Opportunities, Market Size, Share, Growth Drivers, Market Trends, Statistics And Forecast 2015 – 2020 http://www.mrrse.com/turpentine-market
Turpentine is a colorless or yellowish liquid having extremely strong pine-like fragrance. Turpentine is a volatile oil that is extracted from the pine resins which is obtained from the trees of the genus Pinus. Turpentine is composed of terpenes which mainly consist of the monoterpenes such as alpha-pinene and beta-pinene with small quantities of careen, dipentene, camphene and terpinolene. Turpentine is often replaced by mineral turpentine or other petroleum distillates which are very different chemically. Turpentine is easily soluble in non-polar solvents, acetone, diethyl ether and absolute ethanol among others. Turpentine finds wide applications as solvents for paints, enamels and varnishes as well as raw material for manufacturing important products.
•
Tetramer Market - Global Industry Expert Opinions Analysis, Emerging Opportunities, Market Size, Share, Growth Drivers, Market Trends, Statistics And Forecast 2015 – 2020 http://www.mrrse.com/tetramer-market
Tetramer is an olefin with a branched structure. It is also known as propylene tetramer, dodecene or isododecene. It is a colorless clear liquid and has a mild pleasant odor. Tetramer is soluble in most organic solvents such as ethanol, ethyl ether, acetone, etc. and insoluble in water. Tetramer is manufactured synthetically in the industry by oligomerization of propylene. The product mixture consists of several isomeric olefin compounds with the double bond located at different positions and varying amount of branching. Tetramer is highly combustible material and is utilized in the industries only. Tetramer has a high vapor pressure and a low flash point of 58 degrees Celsius. Exposure to tetramer may cause irritation on the skin and eyes along with headache and dizziness. If ingested tetramer is hazardous and may cause inflammation and edema in the lungs. Tetramer
is not toxic and has zero potential for bioaccumulation as it is a volatile organic compound (VOC) and degrades rapidly in the atmosphere.
About Us Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. Headquartered in New York, U.S., MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords. MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.
Contact Us: State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 Email: sales@mrrse.com Website: http://www.mrrse.com/ Blog: http://mrrse.blogspot.com/